SER-109 is an investigational oral microbiota-based product for fecal microbiota transplantation (FMT) proposed to prevent recurrent Clostridioides (formerly Clostridium) difficile infection (CDI) in adults with a history of 3 or more CDI episodes within a 12-month period.

If you have a Hayes login, click here to view the full report on the Knowledge Center.